Hangzhou Jiuyuan Gene Engineering Launches Up to HK$570 Million Hong Kong IPO

MT Newswires Live11-20 08:31

Hangzhou Jiuyuan Gene Engineering (HKG:2566) launched its initial public offering in Hong Kong Wednesday, seeking to raise up to HK$570.2 million from the deal.

The genetic engineering company is offering up to 45,398,800 shares expected to be priced between HK$11.48 and HK$12.56 per share, according to a Wednesday filing with the Hong Kong Exchange.

Jiuyuan Gene Engineering expects to determine the IPO price on Nov. 26 and disclose allocation results on Nov. 27. Shares will begin trading on the stock exchange on Nov. 28.

The genetic engineering company intends to use the proceeds for continuing research and development, marketing of existing and near-commercialized products, collaborations, construction and upgrade of production facilities, and working capital.

Hangzhou Jiuyuan Gene Engineering attracted Heda Jinyuan (HK), Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) subsidiary Fosun Industrial, Nanjing King-Friend Biochemical Pharmaceutical (SHA:603707) subsidiary Hong Kong King-Friend Industrial, Alibaba Health (HKG:0241) subsidiary Alibaba Health (Hong Kong) Technology, Jointown Pharmaceutical (SHA:600998) subsidiary Jointown International Group, shareholder Wu Qiyuan, and Delta Capital Hong Kong, as cornerstone investors.

Huatai Financial Holdings (Hong Kong), CLSA, CMB International Capital, Ruibang Securities, and Patrons Securities, are the joint bookrunners and lead managers of the IPO.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484186420?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-20 08:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484186420","market":"us","top_or_hot":-1,"title":"Hangzhou Jiuyuan Gene Engineering Launches Up to HK$570 Million Hong Kong IPO","media":"MT Newswires Live","content":"<html><body><p> Hangzhou Jiuyuan Gene Engineering (HKG:2566) launched its initial public offering in Hong Kong Wednesday, seeking to raise up to HK$570.2 million from the deal.</p><p>The genetic engineering company is offering up to 45,398,800 shares expected to be priced between HK$11.48 and HK$12.56 per share, according to a Wednesday filing with the Hong Kong Exchange.</p><p>Jiuyuan Gene Engineering expects to determine the IPO price on Nov. 26 and disclose allocation results on Nov. 27. Shares will begin trading on the stock exchange on Nov. 28.</p><p>The genetic engineering company intends to use the proceeds for continuing research and development, marketing of existing and near-commercialized products, collaborations, construction and upgrade of production facilities, and working capital.</p><p>Hangzhou Jiuyuan Gene Engineering attracted Heda Jinyuan (HK), Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) subsidiary Fosun Industrial, Nanjing King-Friend Biochemical Pharmaceutical (SHA:603707) subsidiary Hong Kong King-Friend Industrial, Alibaba Health (HKG:0241) subsidiary Alibaba Health (Hong Kong) Technology, Jointown Pharmaceutical (SHA:600998) subsidiary Jointown International Group, shareholder Wu Qiyuan, and Delta Capital Hong Kong, as cornerstone investors.</p><p>Huatai Financial Holdings (Hong Kong), CLSA, CMB International Capital, Ruibang Securities, and Patrons Securities, are the joint bookrunners and lead managers of the IPO.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hangzhou Jiuyuan Gene Engineering Launches Up to HK$570 Million Hong Kong IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHangzhou Jiuyuan Gene Engineering Launches Up to HK$570 Million Hong Kong IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-20 08:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Hangzhou Jiuyuan Gene Engineering (HKG:2566) launched its initial public offering in Hong Kong Wednesday, seeking to raise up to HK$570.2 million from the deal.The genetic engineering company is ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0823038988.USD","symbol_name":"AMUNDI FUNDS ASIA EQUITY FOCUS  \"A2\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2484186420","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484186420","pubTimestamp":1732062718,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Hangzhou Jiuyuan Gene Engineering  launched its initial public offering in Hong Kong Wednesday, seeking to raise up to HK$570.2 million from the deal.The genetic engineering company is offering up to 45,398,800 shares expected to be priced between HK$11.48 and HK$12.56 per share, according to a Wednesday filing with the Hong Kong Exchange.Jiuyuan Gene Engineering expects to determine the IPO price on Nov. 26 and disclose allocation results on Nov. 27. Shares will begin trading on the stock exchange on Nov. 28.The genetic engineering company intends to use the proceeds for continuing research and development, marketing of existing and near-commercialized products, collaborations, construction and upgrade of production facilities, and working capital.Hangzhou Jiuyuan Gene Engineering attracted Heda Jinyuan , Shanghai Fosun Pharmaceutical  subsidiary Fosun Industrial, Nanjing King-Friend Biochemical Pharmaceutical  subsidiary Hong Kong King-Friend Industrial, Alibaba Health  subsidiary Al","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"89988":"阿里巴巴-WR","600196":"复星医药","600998":"九州通","603707":"健友股份","LU0823038988.USD":"AMUNDI FUNDS ASIA EQUITY FOCUS  \"A2\" (USD) ACC","LU0348816934.USD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"AT\" (USD)","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","LU0345775950.USD":"NINETY ONE GSF ASIAN EQUITY \"A\" (USD) ACC","LU1515016050.SGD":"Blackrock Emerging Markets Equity Income A6 SGD-H","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","LU1196710864.SGD":"Schroder ISF Emerging Markets Multi-Asset A Dis SGD-H","LU0823426308.USD":"法巴中国股票基金","LU0791591158.USD":"ALLSPRING  EMERGING MARKTES EQUITY INCOME \"I\" (USD) ACC","LU0132412106.USD":"abrdn SICAV I - EMERGING MARKETS EQUITY \"A\" (USD) ACC","LU0320764243.SGD":"FTIF - Templeton Emerging Markets A Acc SGD","LU0463099449.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) ACC","BK0175":"白马股","IE00BMPRXR70.SGD":"Neuberger Berman 5G Connectivity A Acc SGD-H","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","SG9999002463.SGD":"LionGlobal China Growth SGD","BK1608":"元宇宙概念","02196":"复星医药","LU0823397103.USD":"BNP PARIBAS SUSTAINABLE ASIA EX-JAPAN EQUITY \"C\" (USD) ACC","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","LU0543330566.HKD":"TEMPLETON BRIC \"A\" (HKD) ACC","LU2257852520.SGD":"JPMorgan Funds - Asia Growth A (acc) SGD","LU0865486749.SGD":"Eastspring Investments - Asian Equity Income AS SGD-H","BK4220":"综合零售","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","SG9999001093.SGD":"United Greater China Fund A Acc SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0320764755.SGD":"FTIF - Templeton Asian Growth A Acc SGD","LU0329678170.USD":"FIDELITY EMERGING ASIA \"A\" (USD) INC","00241":"阿里健康","LU0821914370.USD":"贝莱德亚洲成长领袖A2","LU0051755006.USD":"摩根大通中国A (dist)","LU1044876610.USD":"THREADNEEDLE (LUX) ASIAN CONTRARIAN EQUITY \"ZU\" (USD) ACC","LU0315178854.USD":"EASTSPRING INVESTMENTS ASIAN EQUITY INCOME \"A\" ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU0029875118.USD":"TEMPLETON ASIAN GROWTH \"A\" INC","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","LU0029874905.USD":"TEMPLETON EMERGING MARKETS \"A\" INC","BK4534":"瑞士信贷持仓","LU1770034418.SGD":"ALL CHINA EQUITY \"A\" (SGDHDG) ACC","HBBD.SI":"Alibaba HK SDR 5to1","LU0651946864.USD":"贝莱德新兴市场股票收益A2"},"translate_title":"杭州九源基因工程最多5.7亿港元香港IPO","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"89988":0.6,"600196":0.9,"600998":0.9,"603707":0.9,"02196":0.9,"00241":0.9,"HBBD.SI":0.6},"content_text":"Hangzhou Jiuyuan Gene Engineering (HKG:2566) launched its initial public offering in Hong Kong Wednesday, seeking to raise up to HK$570.2 million from the deal.The genetic engineering company is offering up to 45,398,800 shares expected to be priced between HK$11.48 and HK$12.56 per share, according to a Wednesday filing with the Hong Kong Exchange.Jiuyuan Gene Engineering expects to determine the IPO price on Nov. 26 and disclose allocation results on Nov. 27. Shares will begin trading on the stock exchange on Nov. 28.The genetic engineering company intends to use the proceeds for continuing research and development, marketing of existing and near-commercialized products, collaborations, construction and upgrade of production facilities, and working capital.Hangzhou Jiuyuan Gene Engineering attracted Heda Jinyuan (HK), Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) subsidiary Fosun Industrial, Nanjing King-Friend Biochemical Pharmaceutical (SHA:603707) subsidiary Hong Kong King-Friend Industrial, Alibaba Health (HKG:0241) subsidiary Alibaba Health (Hong Kong) Technology, Jointown Pharmaceutical (SHA:600998) subsidiary Jointown International Group, shareholder Wu Qiyuan, and Delta Capital Hong Kong, as cornerstone investors.Huatai Financial Holdings (Hong Kong), CLSA, CMB International Capital, Ruibang Securities, and Patrons Securities, are the joint bookrunners and lead managers of the IPO.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Company Corporation","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484186420"}